Provider Alert! Clinical Criteria Revision for Hereditary Angioedema Agents (HAE) effective June 1,2023
Date: June 9, 2023 Attention: All Providers Effective Date: June 1, 2023 Call to action: Texas Children’s Health Plan (TCHP) would like to let providers know that effective June 1, 2023, the Texas Health and Human Services (HHSC) added age and diagnosis restriction for HAE agents. Please see the drugs impacted below: DrugProcedure CodeAgeDiagnosisBerinert®J0597≥ 5 yearsD84.1Kalbitor®J1290≥ 12 yearsD84.1Firazyr®J1744≥ 18 yearsD84.1Takhzyro®J0593≥ 2 yearsD84.1 How this impacts providers: Starting June 1 2023, TCHP will have diagnosis and age restrictions for HAE agents including Berinert®, Kalbitor®, Firazyr® and...
